201 материалов по теме, собраны автоматически из проверенных источников
Researchers at the University of Tsukuba conducted a physician-initiated phase 2 clinical trial of dasatinib in patients with relapsed or refractory T-follicular helper cell lymphoma (TFHL), an aggressive and difficult-to-treat blood cancer. The study identified genetic alterations and features of the immune…
For pediatric patients with high-risk B-cell acute lymphoblastic leukemia (B-ALL), residential fine particulate matter (PM₂.₅) concentrations during induction therapy are associated with positive end-of-induction (EOI) minimal residual disease (MRD), according to a study published in JNCI Cancer Spectrum.
Tecvayli monotherapy approved in EU for relapsed myeloma care Rare Cancer News
More than 120,000 people in the U.S. are living with acute lymphoblastic leukemia (ALL), and 6,000 new cases are diagnosed each year. Of those, more than 3,500 will be in children. Responsible for 75% of all pediatric leukemia diagnoses, ALL is a rapid-onset blood cancer, preventing the body from producing mature…
A more effective and better-tolerated treatment for chronic myeloid leukemia (CML) could improve quality of life for people living with the disease. A new study led by Adelaide University and the South Australian Health and Medical Research Institute (SAHMRI) has provided the first direct evidence that a targeted…
Mexico authorizes its first domestic CAR-T trial for leukemia patients who have exhausted other treatments Latin Times
Network aims to expand clinical trial access for myeloma patients Rare Cancer News
Emerging Immunotherapies and Targeted Agents Advance Treatment of High-Risk Multiple Myeloma HMP Global Learning Network
MRD Assessment Advances Risk Stratification and Treatment Decision-Making in Multiple Myeloma HMP Global Learning Network
The activity of six different genes can help determine survival in patients with acute myeloid leukemia (AML), according to a study published in Science Advances. The findings by researchers at the Center for Genomic Regulation (CRG) in Barcelona lay the foundations for new ways of predicting how patients will fare…